For decades, the easiest way to judge a weight loss drug was also the most obvious: put people on a scale, wait, and see how many pounds disappeared. Simple, tidy, spreadsheet-friendly. The problem is that human health is not a bathroom scale wearing a lab coat.
The modern era of obesity medicine has outgrown old measurement habits. Newer GLP-1 and GIP-based medications have shown effects that reach beyond body weight, including changes in cardiovascular risk, sleep apnea severity, blood pressure, inflammation, waist size, and quality of life. That does not mean every new drug is a miracle, nor does it mean “more weight loss” automatically equals “better treatment.” It means the U.S. Food and Drug Administration should evaluate weight loss drugs with a more complete scoreboard.
The FDA has already taken an important step by releasing updated draft guidance for obesity and overweight drug development in 2025, replacing a much older 2007 framework. That update matters. But the next leap should be bigger: regulators should formally recognize that obesity treatment is not only about losing weight. It is about reducing disease burden, protecting function, preserving muscle, improving daily life, and proving long-term value without pretending that a single percentage can tell the whole story.
Why the old weight loss metrics feel outdated
Traditional obesity drug trials have leaned heavily on two familiar endpoints: average percentage change in body weight and the share of participants who lose at least 5% of baseline weight. Those measures are useful. A 5% reduction can improve several metabolic markers for some patients. It gives researchers a clean benchmark and allows fair comparison across products.
But useful is not the same as sufficient. A person who loses 8% of body weight but also loses strength, stops treatment because of side effects, and regains most of the weight within a year has not experienced the same health outcome as someone who loses 8%, preserves muscle, improves blood pressure, sleeps better, and can walk farther without pain. The scale sees both people as similar. Their lives say otherwise.
This is where the FDA’s metrics for weight loss drugs need modernization. The question should not be, “Did the patient get smaller?” The better question is, “Did the patient get healthier, safer, more functional, and more likely to maintain benefits over time?”
Obesity is a chronic disease, not a swimsuit emergency
One reason metrics matter is that they shape the way society understands treatment. If regulators and trial sponsors focus almost entirely on pounds, the public hears a familiar old message: obesity is mainly about size. That is medically incomplete and socially exhausting.
Obesity is associated with higher risk of hypertension, type 2 diabetes, coronary heart disease, stroke, sleep apnea, certain cancers, joint problems, liver disease, and reduced mobility. In the United States, adult obesity remains common, and severe obesity has increased over the past decade. At the same time, BMI itself has well-known limitations because it does not directly measure body fat, fat distribution, or individual health status.
That means FDA evaluation should reflect the disease complexity. A drug that reduces weight but does not improve meaningful health outcomes should not be treated the same as a drug that reduces cardiovascular events or improves sleep apnea severity. Likewise, a medication that produces dramatic weight loss while raising concerns about tolerability, nutritional adequacy, or lean mass loss deserves careful review beyond the headline number.
The new obesity drug era changed the evidence
The rise of GLP-1 receptor agonists and dual incretin therapies has changed expectations. Semaglutide and tirzepatide have shown weight loss results that earlier medications rarely approached. But even more important, the evidence has expanded beyond body weight.
In 2024, the FDA approved a new indication for semaglutide to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight. That approval was based on outcomes, not just waistbands waving a tiny white flag. In the same year, the FDA approved tirzepatide for moderate to severe obstructive sleep apnea in adults with obesity, using apnea-hypopnea index improvement as a primary measure of efficacy.
Those approvals are a flashing neon sign: the future of obesity-drug evaluation is disease-outcome based. If a medication can reduce serious heart problems or improve sleep-disordered breathing, then body weight is no longer the only star of the show. It is part of the cast.
What the FDA should measure next
The FDA does not need to throw away weight-based endpoints. It should surround them with better companions. A modern framework for evaluating obesity medications should include a balanced set of outcomes that reflects biology, safety, patient experience, and long-term durability.
1. Body composition, not just body weight
When someone loses weight, the body may lose fat mass, lean mass, water, or a combination of all three. For health, fat loss is usually the target; excessive lean mass loss is not a trophy. Skeletal muscle supports mobility, glucose metabolism, balance, and healthy aging. Losing too much of it may create problems, especially for older adults or people already at risk of frailty.
Trials should more consistently measure changes in fat mass, visceral fat, waist circumference, lean mass, and strength. DEXA scans, waist-to-height ratio, grip strength, walking speed, or other practical measures could help regulators understand whether a drug improves body composition rather than merely lowering total weight.
2. Cardiometabolic outcomes
Blood pressure, A1C, triglycerides, cholesterol patterns, liver markers, inflammatory markers, and medication burden are more meaningful than scale movement alone. If two drugs produce similar weight loss but one allows more patients to reduce hypertension or diabetes medication under medical supervision, that difference matters.
For higher-risk populations, cardiovascular outcomes deserve special attention. Major adverse cardiovascular events, heart failure outcomes, kidney outcomes, and mortality are not always feasible in every preapproval trial, but they should be built into longer-term evidence plans when appropriate.
3. Function and quality of life
A person may not describe success as “I lost 12.4% of baseline body weight.” They may say, “I can climb stairs again,” “My knees hurt less,” “I sleep through the night,” or “I can play with my kids without needing a recovery period and a dramatic soundtrack.”
Patient-reported outcomes should be treated as serious evidence when they are collected with validated tools. Mobility, fatigue, pain, sleep quality, physical functioning, stigma, treatment burden, and emotional well-being can show whether a drug changes daily life. These outcomes should not replace safety and efficacy data, but they should help interpret them.
4. Durability after one year and beyond
Obesity is chronic, so short-term results can be misleading. Many people regain weight after stopping anti-obesity medication, and cardiometabolic improvements may fade as weight returns. That does not make the drugs useless; blood pressure medication also works only when used appropriately. But it does mean trials and labels should clearly communicate what happens with continued use, discontinuation, dose changes, and long-term maintenance.
The FDA should encourage evidence on maintenance strategies, real-world persistence, reasons for discontinuation, and outcomes after stopping therapy. A drug that works beautifully for six months but is hard to tolerate for two years raises a different public-health question than a drug with moderate weight loss and excellent durability.
5. Safety that reflects real patients
Side effects are not footnotes; they are part of the treatment experience. Gastrointestinal symptoms, gallbladder issues, pancreatitis warnings, kidney concerns, hypoglycemia risk in certain combinations, mental health monitoring, and rare but serious risks must remain central to FDA review.
Trials should also include diverse populations. Obesity risk, BMI interpretation, fat distribution, access to care, and treatment response can vary by age, sex, race, ethnicity, socioeconomic status, disability, and comorbid disease. If a drug will be used widely, the evidence should not come from a narrow slice of America that looks suspiciously like it was recruited from one very enthusiastic wellness conference.
Why BMI alone cannot carry the weight
BMI is cheap, fast, and easy. That is why it has survived so long. But BMI cannot distinguish a muscular person from someone with high visceral fat. It cannot tell where fat is stored. It cannot measure liver fat, insulin resistance, inflammation, pain, mobility, or sleep quality.
For population screening, BMI still has value. For individual treatment decisions and drug evaluation, it should be only one part of a broader assessment. Waist circumference, waist-to-height ratio, body composition, metabolic markers, and clinical complications can provide a clearer picture of risk and benefit.
The FDA’s future obesity-drug framework should help move the market away from “biggest average weight loss wins” and toward “best overall health benefit for the right patient wins.” That is a less flashy headline, but it is better medicine.
The danger of ranking drugs by pounds lost
The public conversation around weight loss drugs often turns into a horse race: Which drug produces the biggest percentage? Which one works fastest? Which one makes the before-and-after photos most dramatic? This may be great for social media engagement, but it is a poor way to evaluate chronic disease treatment.
A medication that produces 20% weight loss may be appropriate for one patient and excessive, poorly tolerated, or unnecessary for another. Someone with cardiovascular disease may need evidence of heart-risk reduction. Someone with sleep apnea may need improvement in breathing events and daytime fatigue. Someone at risk of frailty may need careful monitoring of muscle and nutrition. Someone with obesity-related knee pain may care most about mobility and pain reduction.
The best drug is not always the strongest drug. It is the drug whose benefits match the patient’s medical risks, goals, and ability to stay on treatment safely.
What a smarter FDA framework could look like
A modern FDA framework for weight loss drugs could use a tiered model. The first tier would still include body weight change, because weight reduction remains relevant. The second tier would require evidence of improvement in obesity-related health markers, such as waist circumference, blood pressure, glycemic measures, lipids, liver markers, or sleep apnea metrics. The third tier would include patient-centered outcomes, such as physical function, fatigue, pain, and treatment burden. The fourth tier would examine durability, safety, discontinuation effects, and body composition.
This approach would help separate cosmetic weight loss from medical obesity treatment. It would also reward innovation. Companies developing next-generation therapies would know that preserving lean mass, reducing visceral fat, improving functional outcomes, and lowering complication risk are not optional decorations. They are part of the value proposition.
Examples of better success stories
Imagine three patients in a clinical trial. Patient A loses 18% of body weight but stops treatment because side effects make daily life miserable. Patient B loses 10%, improves blood pressure, reduces sleep apnea severity, and reports better mobility. Patient C loses 7%, preserves lean mass, improves A1C, and maintains results for two years.
Under a narrow weight-loss lens, Patient A looks like the superstar. Under a health-centered lens, Patients B and C may represent more meaningful treatment success. The FDA’s metrics should be sophisticated enough to see that difference.
Why this matters for cost, coverage, and trust
Weight loss drugs are expensive, and access remains uneven. Insurers, employers, Medicare policy makers, clinicians, and patients all look to FDA decisions as a signal of value. If approval standards emphasize only body weight, coverage debates may become shallow. If standards include disease outcomes, function, safety, and durability, payers can make better decisions about who benefits most.
Better metrics could also improve public trust. Many people worry that obesity medications are being marketed faster than the health system can responsibly manage them. Stronger endpoints would show that regulators are not approving drugs because they create slimmer charts. They are evaluating whether medications improve health in ways that matter.
Experience-based reflections: what patients, clinicians, and families actually notice
In real life, weight loss treatment rarely feels like a clean clinical-trial graph. It feels like appointments, questions, grocery changes, side effects, hopes, plateaus, insurance forms, and the strange emotional experience of having people suddenly comment on your body as if they have been appointed chair of the Compliment Committee.
From a patient’s perspective, the most meaningful improvements often arrive quietly. A person may notice that they no longer wake up gasping at night. They may tie their shoes without holding their breath. They may walk through an airport without planning every bench stop like a military operation. They may reduce knee pain enough to take a longer walk. These changes do not always map neatly onto a weight percentage, but they can transform daily life.
Clinicians often see another side: the medication is only one tool. A patient may lose weight but struggle to eat enough protein, maintain resistance exercise, manage nausea, or afford refills. Another patient may lose less weight but develop better blood pressure, improved sleep, and a more stable relationship with food. A third may stop therapy because of cost and regain weight quickly, not because of moral failure but because biology is extremely good at defending lost weight. The body, unfortunately, does not read motivational quotes.
Families also notice outcomes that trials may under-measure. They notice whether someone has more energy after work, whether they join activities again, whether they seem less limited by pain, whether food becomes less of a constant mental negotiation, and whether treatment creates stress because of side effects or expense. These lived experiences should not replace rigorous endpoints, but they should help define what “effective” means.
The FDA has a chance to bring these realities into the science. Patient experience data can be structured, validated, and analyzed. Functional outcomes can be measured. Body composition can be tracked. Long-term maintenance can be studied. The goal is not to make approval easier or harder for the sake of bureaucracy. The goal is to make approval smarter.
A better system would also protect patients from hype. When advertisements, influencers, and headlines focus on dramatic weight loss, people may assume the highest number is automatically best. Regulators can counter that by requiring clearer evidence about who benefits, what risks exist, how long benefits last, and what outcomes improve beyond weight. That would help clinicians prescribe more thoughtfully and help patients ask better questions.
Ultimately, the experience of obesity treatment is personal, medical, and long-term. A number on the scale may start the conversation, but it should not end it. The future of obesity-drug evaluation should honor the full picture: heart health, breathing, mobility, strength, safety, sustainability, and quality of life. That is where real progress lives.
Conclusion: the FDA should measure health, not just weight
It is time for the FDA to re-evaluate metrics for weight loss drugs because the science has moved beyond the scale. Weight loss remains important, but it is not the entire definition of success. Modern obesity medications can affect cardiovascular risk, sleep apnea, metabolic health, body composition, and daily function. The regulatory framework should reflect that complexity.
A smarter FDA approach would keep weight-based endpoints while adding stronger requirements for cardiometabolic outcomes, body composition, patient-reported function, long-term maintenance, safety, and real-world relevance. That would encourage better drugs, better trials, better labels, and better conversations between clinicians and patients.
The future of obesity treatment should not be a contest to see which medication makes the scale drop fastest. It should be a serious effort to identify which therapies help people live healthier, safer, stronger, and more sustainable lives. The scale can still have a seat at the table. It just should not be allowed to run the meeting.
